Can Rocket Lab’s Space Systems business carry the cash cost of Neutron and the dilution from buying Iridium? Q2 evidence says the operating base is becoming materially stronger: revenue reached $234.1 million, Space Systems supplied 81.0% of it, and consolidated gross margin improved to 36.1%. The equity case is still demanding. Neutron’s first flight has moved to 2027, the Iridium acquisition changes both leverage and share count, and our conditional October 2027 Bear/Base/Bull values are $26.48 / $49.65 / $85.67. The Base case sits close to the market reference and requires rapid organic growth; it does not offer a clear margin of safety.
AHNIM STUDIO · Company Research · Nasdaq: RKLB
Assessment: October 25, 2026 (Asia/Seoul). Financial statements: consolidated US GAAP through June 30, 2026. All monetary figures are USD, generally millions. Target date: approximately October 2027, using FY2028 operations. Market reference: $52.60 at the October 23, 2026 US close, the latest completed regular session. The quote is a time-stamped reference, not an assumed execution price. Market and analyst reference
1. Rocket Lab is already more than a launch company
Rocket Lab reports two segments. Launch Services sells dedicated and rideshare missions through Electron and HASTE while developing the reusable medium-lift Neutron vehicle. Space Systems supplies spacecraft, satellite components, solar power, separation systems, guidance and communications hardware, and mission services. The company has expanded that stack through acquisitions including Sinclair, SolAero, GEOST, Mynaric and Motiv. Q2 2026 Form 10-Q
The economic question is not whether rockets are strategically interesting. It is whether the current products can compound gross profit fast enough to fund Neutron, absorb integration risk and leave value for each share. Launch gives Rocket Lab customer access and vertical integration. Space Systems supplies the larger present revenue base. Iridium, if the pending transaction closes, would add a recurring communications network and spectrum—but also financing, integration and regulatory dependencies.
This is why we treat Electron, Neutron and Iridium as different stages of evidence. Electron has a flight record and recognized revenue. Space Systems has recognized product revenue and backlog. Neutron has hardware and contracts but no inaugural flight. Iridium remains a pending acquisition despite shareholder approval and financing progress. One stage should not be presented as proof that the next stage is complete.
2. Q2: growth improved the income statement, not yet the cash flow
| Metric / USDm unless noted | Q2 2025 | Q2 2026 | AHNIM reading |
|---|---|---|---|
| Revenue | 144.498 | 234.066 | +62.0% YoY |
| Launch Services revenue | 46.646 | 44.586 | −4.4% YoY |
| Space Systems revenue | 97.852 | 189.480 | +93.6% YoY; 81.0% of total |
| GAAP gross profit | 46.388 | 84.576 | 36.1% margin vs. 32.1% |
| Launch Services gross margin | 30.5% | 42.9% | Higher margin despite lower revenue |
| Space Systems gross margin | 32.9% | 34.6% | Scale improved, but mix matters |
| GAAP operating loss | (59.639) | (57.514) | Loss narrowed only modestly |
| GAAP net loss | (66.414) | (49.258) | Interest income helped |
The mix is the first important finding. Space Systems produced $189.5 million of Q2 revenue, almost four times Launch Services revenue. Launch is strategically prominent, but today’s income statement is mostly hardware and spacecraft activity. A valuation that treats all revenue as if it were high-margin launch-network revenue overstates the evidence. Concentration also matters: one government customer represented 42% of first-half revenue, and MDA represented 11% of accounts receivable at June 30. Those are disclosed concentrations, not proof of a loss, but they raise the importance of program execution and collection timing. Q2 2026 Form 10-Q
The second finding is that gross-profit growth has not yet reached operating cash generation. Q2 R&D expense was $82.4 million, up 25% year over year, primarily because of Neutron progress, acquired businesses, hiring and spacecraft development. For the first half, operating cash outflow was $134.4 million and cash purchases of property, equipment and software were $53.1 million. Their sum was $187.5 million of cash use. This is not a company-reported free-cash-flow metric; it is our simple operating-cash-flow-less-capex check and excludes acquisitions and financing.
Working capital consumed cash as inventories, receivables and contract assets grew. Contract liabilities rose to $351.2 million, partly offsetting that use. Customer advances can finance production, but they also represent future work. Backlog was $2.36 billion at quarter end and management said contracts are included when an enforceable agreement is reached. Backlog supports visibility; it is not revenue, profit or collected cash.
3. Guidance sets a higher revenue bar while losses remain
Management guided Q3 revenue to $250–265 million, GAAP gross margin to 29–31%, GAAP operating expenses to $143–149 million and adjusted EBITDA loss to $17–23 million. The revenue midpoint of $257.5 million would be another record, but the guided GAAP margin is below Q2’s 36.1%. Acquisitions, program mix and execution can move margin between quarters. We would not extrapolate one quarter’s segment margin unchanged into a mature model. Q2 results and Q3 guidance
Our next check is whether Space Systems converts its growth into repeatable gross profit without requiring working-capital growth at the same pace. The strongest version of the thesis is not simply “more backlog.” It is backlog turning into revenue, gross profit and cash while customer concentration and program risk remain manageable.
4. Neutron’s 2027 delay separates first flight from commercial cadence
Rocket Lab’s October 14 filing moved Neutron’s inaugural launch into 2027 without naming a quarter. In the accompanying investor update, management described manufacturing work after voids were found in a carbon-fiber propellant dome made with the automated fiber-placement process. Management said specified tank milestones should be completed before and during Q1 2027, after which it would set a new launch date. The 2027 change is confirmed in the October 14 SEC exhibit; the technical details and milestone sequence are attributed to Via Satellite’s account of the investor presentation.
A successful first flight would be important evidence; it would not establish regular cadence, acceptable unit economics or full contract conversion. The sequence is manufacturing quality, completed testing, pad readiness, first flight, repeatability and customer missions. Our separate Neutron schedule analysis explains why a calendar change first affects development spending and the timing of future cash, not historical Space Systems revenue.
Neutron matters because medium lift expands the addressable launch market and can support Rocket Lab’s own future constellation economics. It also concentrates technical risk. An additional dollar of R&D can create value if it raises reliability and future cadence. It destroys value if repeated delays consume capital without proportionate progress. We do not assign a fixed monthly cost to the delay because the company has not disclosed one.
5. Iridium adds recurring cash flow—and a new capital structure
Rocket Lab agreed to acquire Iridium for $27 cash plus Rocket Lab shares under a collar, with a stated $54 notional value per Iridium share and approximately $8.0 billion enterprise value. The exchange ratio is 0.4000 when Rocket Lab’s reference stock price is at or below $67.50, $27 divided by the reference price between $67.50 and $112.50, and 0.2400 at or above $112.50. The company expects closing in mid-2027, subject to remaining regulatory and other conditions. Iridium shareholders approved the transaction on September 24. Merger terms in Rocket Lab’s 10-Q · Shareholder approval
Iridium reported 2025 revenue of $871.7 million and operational EBITDA of $495 million, a 57% margin, in the transaction announcement. That recurring network profile can reduce dependence on project timing and supply cash for growth. It also comes with debt and constellation-replacement obligations. We do not treat the acquired EBITDA as cash freely distributable to Rocket Lab shareholders without interest, capital expenditure, tax and integration costs.
Financing is already visible in the share count. At June 30, Rocket Lab had 598.18 million common shares outstanding plus 40.95 million economically convertible preferred shares. On September 15, the company said it had completed an ATM offering of 29.3 million additional shares for approximately $1.944 billion of gross proceeds. On that mechanical basis, common plus convertible preferred equivalents rise to approximately 668.4 million before acquisition shares, employee awards and other instruments. September financing update
Iridium’s $1.775 billion term loan was amended to remain outstanding after closing, and Rocket Lab USA is expected to guarantee it. The earlier $3.6 billion bridge commitment was terminated. The ATM reduced financing uncertainty but converted part of the transaction cost into permanent equity dilution. This is not automatically negative: per-share value can rise if acquired cash flows and strategic options exceed the value transferred. The correct test is the return on the enlarged share and debt base.
6. Liquidity is large, but not all of it is excess cash
| Capital item | Amount | What it means |
|---|---|---|
| Cash and cash equivalents | $2,129.5m | June 30 balance |
| Current + non-current marketable securities | $258.1m | June 30 balance |
| Cash + securities | $2,387.6m | Historical, before September ATM and acquisition uses |
| H1 operating cash flow | $(134.4)m | Operating cash use |
| H1 cash capex | $(53.1)m | Property, equipment and software |
| September ATM | $1,944m gross | 29.3m new shares; intended mainly for Iridium cash consideration |
| Iridium term loan | $1,775m | Expected to remain outstanding and be guaranteed after close |
The Q2 balance sheet was strong because equity issuance had already raised capital. It should not be interpreted as a fixed Neutron runway independent of the Iridium transaction. Rocket Lab said the ATM proceeds, existing liquidity and retained Iridium loan provide enough funding for the cash consideration, certain debt repayment and fees. That statement addresses transaction financing. It does not guarantee Neutron timing, integration success or positive consolidated free cash flow.
7. Conditional valuation: the current price already requires strong execution
We use a sum-of-parts framework for an approximately October 2027 target date, based on FY2028 operations. “Organic Rocket Lab” means the existing launch and Space Systems businesses excluding Iridium. We apply forward enterprise-value-to-revenue multiples because Rocket Lab remains loss-making and Neutron has no mature earnings base. Iridium is valued separately at enterprise value. We then subtract pro forma net debt and divide by a diluted share assumption that includes the June share base, September ATM, expected merger shares and continuing equity compensation.
| October 2027 target using FY2028 | Bear | Base | Bull |
|---|---|---|---|
| Organic Rocket Lab revenue | $1.5bn | $2.0bn | $2.7bn |
| Organic EV / revenue | 8× | 13× | 18× |
| Organic enterprise value | $12.0bn | $26.0bn | $48.6bn |
| Iridium enterprise value | $8.0bn | $10.0bn | $12.0bn |
| Less pro forma net debt | $0.8bn | $0.5bn | $0.2bn |
| Equity value | $19.2bn | $35.5bn | $60.4bn |
| Diluted shares | 725m | 715m | 705m |
| Value per share | $26.48 | $49.65 | $85.67 |
The Base case is demanding. Organic FY2028 revenue of $2.0 billion requires the existing business to grow rapidly from a 2026 run rate near $1 billion. A 13× forward-revenue multiple also assumes durable strategic value and improving economics before mature profit is visible. The $10 billion Iridium value credits growth above the announced transaction enterprise value. At $49.65, the Base case is 5.6% below the $52.60 October 23 closing reference. That difference is not a buy or sell signal; it says execution, not obvious undervaluation, dominates the return.
The 8×/13×/18× multiples deliberately widen with the operating outcome: the Bear case assumes slower growth and less confidence in eventual margins, while the Bull case assumes scarce launch capacity and integrated space infrastructure retain a premium. Diluted shares move in the opposite direction—725 million in Bear, 715 million in Base and 705 million in Bull—because weaker execution is more likely to require additional equity funding. These are transparent sensitivities, not predictions of the exact future share count.
The Bear case still assigns $8 billion to Iridium and 8× FY2028 organic revenue. It is not a liquidation case. The Bull case requires both $2.7 billion of organic revenue and an 18× multiple, while dilution and net debt stay contained. If Iridium does not close, this framework must be rebuilt rather than mechanically subtracting its enterprise value: unused financing, break costs and the standalone balance sheet would all change.
8. Broker targets are materially above our Base case
Post-delay target actions were not uniformly bullish. A secondary-source table checked October 25 lists Citizens at $130→$90 with Buy maintained on October 16 and KeyBanc at $135→$100 with Buy maintained on October 15; it lists Stifel at $132 unchanged, Needham at $120 unchanged and Cantor Fitzgerald at $122 unchanged. We could not inspect the underlying broker notes, so the dates, ratings and targets are attributed to the aggregator rather than presented as primary research. The same table shows a $102.15 average 12-month target from 20 analysts, while StockAnalysis reports the identical $102.15 average with a 22-analyst Buy consensus. Sample definitions therefore differ. Using the 22-analyst StockAnalysis figure, our $49.65 Base value is 51.4% below the average, calculated as |49.65 − 102.15| ÷ 102.15. The comparison is directionally useful but not perfectly like-for-like: both are approximately one-year values, while our method explicitly uses FY2028 revenue and a conditional Iridium close. Investing.com target table · StockAnalysis consensus
The gap reflects assumptions, not a claim that the consensus is wrong. Our Base multiple is already high, we reserve value for dilution and debt, and we do not treat first flight or the acquisition announcement as completed cash generation. Our value would move higher if Neutron clears manufacturing and flight milestones, Space Systems converts backlog with sustained margins, Iridium closes without adverse remedies, and per-share cash flow improves faster than dilution. It would move lower with further schedule slips, weaker gross margin, integration costs or a higher pro forma share count.
9. What would change our view
- Neutron: completed dome and stage testing, a disclosed launch window, successful first flight and evidence of repeatable manufacturing—not the first flight alone.
- Space Systems: backlog conversion, gross profit and working-capital discipline across acquired operations.
- Electron and HASTE: launch cadence and margin without assuming every scheduled mission flies in the same quarter.
- Iridium: remaining regulatory approvals, final exchange ratio, closing balance sheet, integration costs and post-close capital expenditure.
- Per-share economics: diluted shares, stock compensation, debt and cash flow after transaction financing.
Rocket Lab has built a broader and stronger operating platform than the launch narrative alone suggests. Space Systems is already the revenue engine, Electron supplies proven launch capability, and Iridium could add recurring network cash flow. But the share price asks investors to pay today for several future handoffs: growth to margin, margin to cash, Neutron hardware to cadence, and an acquisition to per-share value. Our Base case does not yet provide a meaningful margin of safety.
Three findings
- Space Systems generated 81.0% of Q2 revenue, making current RKLB economics far less launch-dependent than the headline narrative.
- Liquidity is substantial, but 29.3 million September ATM shares and the pending Iridium stock consideration make dilution part of the operating thesis.
- Our $49.65 Base value is 5.6% below the latest completed US closing reference and 51.4% below the cited 22-analyst average; Neutron cadence and post-deal per-share cash flow are the decisive tests.
Explore the Rocket Lab research hub. This analysis is for information and education, not individualized investment advice.
Sources and original documents
Rocket Lab, Form 10-Q for the quarter ended June 30, 2026, filed August 10, 2026. · Rocket Lab, Q2 2026 results and Q3 guidance, August 10, 2026. · Rocket Lab, Neutron development update, SEC Exhibit 99.1, October 14, 2026. · Via Satellite, account of Rocket Lab’s October 14 Neutron investor presentation, October 15, 2026. · Rocket Lab and Iridium, definitive acquisition announcement, June 29, 2026. · Rocket Lab, Iridium financing and completed ATM update, September 15, 2026. · Rocket Lab, Iridium shareholder approval, September 24, 2026. · Investing.com, broker target table, checked October 25, 2026; secondary aggregation. · StockAnalysis, market close and analyst consensus, checked October 25, 2026; secondary aggregation.
Leave a Reply